FDA authorizes limited prescriptions of Paxlovid by pharmacists
The Food and Drug Administration today state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization.
Related News Articles
Headline
The Department of Health and Human Services July 28 announced the creation of a $100 million pilot program to prevent, test for, treat and cure hepatitis C for…
Headline
Five pediatric flu deaths were reported to the Centers for Disease Control and Prevention last week, pushing the total to 266 for the 2024-2025 flu season,…
Headline
The Department of Health and Human Services July 23 announced it is recommending the removal of thimerosal from all U.S. flu vaccines. The announcement follows…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Centers for Disease Control and Prevention July 7 announced it is streamlining H5N1 bird flu updates with its routine influenza data given the low public…
Headline
The United States July 7 reached its highest annual measles case tally in 33 years, hitting at least 1,277 confirmed cases across 38 states and the District of…